tiprankstipranks
Top Stocks
Top Analyst StocksTop Smart Score StocksTop Insiders Stocks
Popular
Stock ScreenerTop Online Growth StocksTrending StocksPenny Stock Screener
Dividend Investing
Dividend CalculatorDividend Yield CalculatorDividend StocksDividend NewsDividend Calendar
ETFs
ETF CenterSPY ETFQQQ ETF
Stock Comparison
ChatGPT StocksValue StocksAirline StocksAI StocksOil StocksBank StocksFAANG StocksCompare More Stocks…
Calendars
IPO CalendarEarnings Calendar
Popular
Dividend CalendarEconomic Calendar
New
Market HolidaysDaily Analyst RatingsDaily Insider Trading
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
My PortfolioMy PerformanceMy Portfolio AnalysisCrowd InsightsMy Watchlist
About Us
About TipRanksContact Us
Working with TipRanks
Enterprise SolutionsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Smart Score Stocks
Analysts' Hot Stocks
Insiders' Hot Stocks
Popular
Trending Stocks
Fastest Growing Websites
Hot
Penny Stocks
Market Movers
My Experts
Top Firms
Top Wall Street Analysts
Top Financial Bloggers
Top Corporate Insiders
Popular
Top Hedge Fund Managers
Top Individual Investors
Stock Screener
Stock Comparison
Dividend Calculator
Popular
ETF Center
Dividend Yield Calculator
Daily Stock Ratings
Daily Insider Transactions
Stock ComparisonPOPULAR COMPARISONS
Dividend Stocks
ChatGPT Stocks
Airline Stocks
AI Stocks
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
IPO Calendar
Stock Market Holidays
Market News
ETF News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
Tipranks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
About TipRanks
For Business
Become an Affiliate
Reviews
Contact Us
Plans & Pricing

HRTX Stock Latest News

Heron Therapeutics Dives on Zynrelef Troubles
Market NewsHeron Therapeutics Dives on Zynrelef Troubles
4d ago
HRTX
Heron Therapeutics price target lowered to $10 from $15 at Evercore ISI
The FlyHeron Therapeutics price target lowered to $10 from $15 at Evercore ISI
5d ago
HRTX
Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Highlights Recent Corporate Updates
Press ReleasesHeron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Highlights Recent Corporate Updates
5d ago
HRTX
Heron Therapeutics reports Q4 EPS (17c), consensus (28c)
The FlyHeron Therapeutics reports Q4 EPS (17c), consensus (28c)
5d ago
HRTX
Heron announces CMS granted pass-through payment status for APONVIE
The FlyHeron announces CMS granted pass-through payment status for APONVIE
16d ago
HRTX
Heron says CMS granted pass-through payment status for Aponvie
The FlyHeron says CMS granted pass-through payment status for Aponvie
16d ago
HRTX
Heron Therapeutics announces U.S. commercial launch of APONVIE
The FlyHeron Therapeutics announces U.S. commercial launch of APONVIE
23d ago
HRTX
Heron Therapeutics announces cooperation agreement with Rubric and Velan
The FlyHeron Therapeutics announces cooperation agreement with Rubric and Velan
1M ago
HRTX
Heron Therapeutics Flies Upward on New Investors
Market NewsHeron Therapeutics Flies Upward on New Investors
2M ago
HRTX
Heron Therapeutics Highlights Progress in Acute Care and Oncology Care Franchises
Press ReleasesHeron Therapeutics Highlights Progress in Acute Care and Oncology Care Franchises
3M ago
HRTX
Wall Street Screams Buy for This Biotech Name Despite a 73% Correction
Market NewsWall Street Screams Buy for This Biotech Name Despite a 73% Correction
3M ago
HRTX
Heron Therapeutics announces filing of sNDA for ZYNRELEF
The FlyHeron Therapeutics announces filing of sNDA for ZYNRELEF
3M ago
HRTX
Heron Therapeutics reports Q3 EPS (38c), consensus (38c)
The FlyHeron Therapeutics reports Q3 EPS (38c), consensus (38c)
5M ago
HRTX
Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Highlights Recent Corporate Updates
Press ReleasesHeron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Highlights Recent Corporate Updates
5M ago
HRTX
Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Highlights Recent Corporate Updates
Press ReleasesHeron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Highlights Recent Corporate Updates
5M ago
HRTX
Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Highlights Recent Corporate Updates
Press ReleasesHeron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Highlights Recent Corporate Updates
8M ago
HRTX
2 “Strong Buy” Stocks With Heavy Short Interest
Stock Analysis & Ideas2 “Strong Buy” Stocks With Heavy Short Interest
2y ago
CRSR
HRTX
2 “Strong Buy” Biotech Stocks With Major Catalysts Approaching
Stock Analysis & Ideas2 “Strong Buy” Biotech Stocks With Major Catalysts Approaching
2y ago
ARDX
HRTX
Heron Therapeutics: HTX-011 Will Eventually Be Approved, Says Analyst
Stock Analysis & IdeasHeron Therapeutics: HTX-011 Will Eventually Be Approved, Says Analyst
3y ago
HRTX
Billionaire Jim Simons Pulls the Trigger on These 3 Healthcare Stocks
Stock Analysis & IdeasBillionaire Jim Simons Pulls the Trigger on These 3 Healthcare Stocks
3y ago
HRTX
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert CenterEtf Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.